Zeruesenay Desta

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. pmc Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation
    Evan T Ogburn
    Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Drug Metab Dispos 38:1218-29. 2010
  2. ncbi request reprint The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6
    Zeruesenay Desta
    Division of Clinical Pharmacology, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA
    Drug Metab Dispos 30:336-43. 2002
  3. pmc Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age
    Z Desta
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 90:693-700. 2011
  4. pmc Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test
    Zeruesenay Desta
    Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Pharmacol Exp Ther 329:297-305. 2009
  5. ncbi request reprint Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6
    Zeruesenay Desta
    Indiana University School of Medicine, Department of Medicine Division of Clinical Pharmacology, 1001 West 10th Street, WD Myers Bldg, W7123, Indianapolis, IN 46202, USA
    J Pharmacol Exp Ther 310:1062-75. 2004
  6. ncbi request reprint Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
    Zeruesenay Desta
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 1001 West 10th Street, WD Myers Bldg, W7123, Indianapolis, IN 46202, USA
    Pharmacogenomics 8:547-58. 2007
  7. ncbi request reprint In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin
    Zeruesenay Desta
    Division of Clinical Pharmacology, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA
    J Clin Psychopharmacol 22:162-8. 2002
  8. pmc Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo
    Cong Xu
    Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Drug Metab Dispos 40:717-25. 2012
  9. pmc Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A
    Seongwook Jeong
    Division of Clinical Pharmacology, Department of Medicine, Indiana University, Indianapolis, USA
    Antimicrob Agents Chemother 53:541-51. 2009
  10. pmc A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes
    Lang Li
    Division of Biostatistics, Department of Medicine, Indiana University, Indianapolis, Indiana46202, USA
    J Biopharm Stat 18:1150-77. 2008

Research Grants

  1. CYP2B6 genetic variations and drug interactions
    Zeruesenay Desta; Fiscal Year: 2007
  2. CYP2B6 genetic variations and drug interactions
    Zeruesenay Desta; Fiscal Year: 2009
  3. CYP2B6 genetic variations and drug interactions
    Zeruesenay Desta; Fiscal Year: 2010
  4. CYP2B6 genetic variations and drug interactions
    Zeruesenay Desta; Fiscal Year: 2010

Collaborators

Detail Information

Publications50

  1. pmc Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation
    Evan T Ogburn
    Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Drug Metab Dispos 38:1218-29. 2010
    ..Efavirenz may be a valuable dual phenotyping tool to study CYP2B6 and CYP2A6, and this should be further tested in vivo...
  2. ncbi request reprint The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6
    Zeruesenay Desta
    Division of Clinical Pharmacology, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA
    Drug Metab Dispos 30:336-43. 2002
    ..Metoclopramide elimination is likely to be slowed in poor metabolizers of CYP2D6 or in patients taking inhibitors of this isoform, whereas metoclopramide itself could reduce the clearance of CYP2D6 substrate drugs...
  3. pmc Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age
    Z Desta
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 90:693-700. 2011
    ..CYP2A6 metabolic status, along with BMI and age, may serve as a biomarker of the efficacy of letrozole treatment or a predictor of adverse effects...
  4. pmc Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test
    Zeruesenay Desta
    Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Pharmacol Exp Ther 329:297-305. 2009
    ..74; p = 0.038). These feasibility data suggest that the [(13)C]pantoprazole breath test is a reliable, rapid, and noninvasive probe of CYP2C19 and seems to be a useful tool to optimize drug therapy metabolized by CYP2C19...
  5. ncbi request reprint Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6
    Zeruesenay Desta
    Indiana University School of Medicine, Department of Medicine Division of Clinical Pharmacology, 1001 West 10th Street, WD Myers Bldg, W7123, Indianapolis, IN 46202, USA
    J Pharmacol Exp Ther 310:1062-75. 2004
    ..Variable activity of these P450s, brought about by genetic polymorphisms and drug interactions, may alter the balance of TAM effects in vivo...
  6. ncbi request reprint Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
    Zeruesenay Desta
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 1001 West 10th Street, WD Myers Bldg, W7123, Indianapolis, IN 46202, USA
    Pharmacogenomics 8:547-58. 2007
    ..To determine the influence of cytochrome P450 2B6 (CYP2B6) genotype on the rate of oxidative efavirenz metabolism in human liver microsomes...
  7. ncbi request reprint In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin
    Zeruesenay Desta
    Division of Clinical Pharmacology, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA
    J Clin Psychopharmacol 22:162-8. 2002
    ..In addition, the possibility that these drugs could alter pimozide disposition through effects on transport proteins or via promoter repression cannot be ruled out...
  8. pmc Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo
    Cong Xu
    Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Drug Metab Dispos 40:717-25. 2012
    ..1 μM). In conclusion, our data suggest the CYP2B6*6 allele influences metabolic activity by altering substrate binding and catalytic activity in a substrate- and Cyt b5-dependent manner. It may also confer susceptibility to inhibition...
  9. pmc Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A
    Seongwook Jeong
    Division of Clinical Pharmacology, Department of Medicine, Indiana University, Indianapolis, USA
    Antimicrob Agents Chemother 53:541-51. 2009
    ..Clinicians should be aware of these interactions and monitor patients for adverse effects or failure of therapy...
  10. pmc A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes
    Lang Li
    Division of Biostatistics, Department of Medicine, Indiana University, Indianapolis, Indiana46202, USA
    J Biopharm Stat 18:1150-77. 2008
    ..The mixture model approach has the highest recovery probability to recover the true partition in the simulation studies. Its applications are exemplified in interim data analyses for two cancer studies...
  11. ncbi request reprint CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Yan Jin
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Natl Cancer Inst 97:30-9. 2005
    ....
  12. pmc Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole
    Lauren Nicole Bell
    Division of Clinical Pharmacology, Wishard Memorial Hospital, WD Myers Bldg, W7123, 1001 West 10th St, Indianapolis, IN 46202, USA
    J Clin Pharmacol 52:1852-60. 2012
    ..In conclusion, AI treatment and/or washout of tamoxifen induced detrimental changes in the lipid profile of postmenopausal women with breast cancer...
  13. ncbi request reprint Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment
    Silvana Borges
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Pharmacol Ther 80:61-74. 2006
    ..We conducted a prospective trial in 158 patients with breast cancer who were taking tamoxifen to further understand the effect of CYP2D6 genotype and concomitant medications on endoxifen plasma concentrations...
  14. ncbi request reprint Estimating a positive false discovery rate for variable selection in pharmacogenetic studies
    Lang Li
    Department of Medicine, Division of Biostatistics, Indiana University, Indianapolis, Indiana 46202, USA
    J Biopharm Stat 17:883-902. 2007
    ..Data analysis is illustrated with a pharmacogenetics example...
  15. doi request reprint Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin
    Rolf P Kreutz
    Krannert Institute of Cardiology, Indiana University School of Medicine, IN 46202, USA
    Platelets 24:145-50. 2013
    ..Addition of PGE1 to ADP agonist platelet assays may identify subjects with blunted inhibitory response to prostaglandins and result in a higher proportion of subjects with DM being classified as non-responders...
  16. doi request reprint Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients
    Silvana Borges
    Division of Biostatistics Clinical Pharmacology, Indiana University, School of Medicine, 410 W 10th St, HITS 3000, Indianapolis, IN 46202 e mail
    J Clin Pharmacol 50:450-8. 2010
    ..However, endoxifen phenotypes still varied substantially, even with incorporation of CYD2D6 genotype and inhibiting factors, suggesting that other, as yet unidentified factors must be involved in tamoxifen activation...
  17. ncbi request reprint Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    Vered Stearns
    The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Natl Cancer Inst 95:1758-64. 2003
    ..In a prospective clinical trial, we tested the effects of coadministration of tamoxifen and the SSRI paroxetine, an inhibitor of CYP2D6, on tamoxifen metabolism...
  18. pmc Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?
    David L Thacker
    Indiana University School of Medicine, Indiana University, Indianapolis, IN, USA
    J Breath Res 7:016001. 2013
    ..Thus, racemic [(13)C]-pantoprazole which is relatively easy to synthesize and more stable than (+)-[(13)C]-pantoprazole is adequate as a probe of this enzyme...
  19. ncbi request reprint Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells
    Young Chai Lim
    Division of Clinical Pharmacology, Indiana University School of Medicine, 1001 West 10th Street, WD Myers Bldg, W7123, Indianapolis, IN 46202, USA
    J Pharmacol Exp Ther 318:503-12. 2006
    ..We conclude that endoxifen and 4-OH-Tam have similar effects on global gene expression patterns in MCF-7 cells and that the majority of the affected genes are estrogen-regulated genes...
  20. ncbi request reprint The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
    Bryan A Ward
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Pharmacol Exp Ther 306:287-300. 2003
    ..Efavirenz may be a valuable phenotyping tool to study the role of CYP2B6 in human drug metabolism...
  21. pmc Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro
    Seongwook Jeong
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Cancer Chemother Pharmacol 64:867-75. 2009
    ..To determine the inhibitory potency of letrozole and its main human metabolite, 4,4'-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes...
  22. ncbi request reprint QT analysis: a complex answer to a 'simple' problem
    Lang Li
    Division of Biostatistics, Department of Medicine, Indiana University 46202 2678, USA
    Stat Med 23:2625-43. 2004
    ..1-0.2 ms). The two-step off-drug QT correction analysis is shown to be almost as efficient as our one-step off- and on-drug QT analysis...
  23. ncbi request reprint Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism
    James M Rae
    Division of Clinical Pharmacology, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA
    Drug Metab Dispos 30:525-30. 2002
    ..Furthermore, thioTEPA may prove to be a valuable new tool for the study of this important drug-metabolizing enzyme...
  24. pmc Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro
    Bryan A Ward
    Indiana University School of Medicine, Department of Medicine Division of Clinical Pharmacology, 1001 West 10th Street, OPD W 320, Indianapolis, Indiana, USA
    Br J Clin Pharmacol 58:277-87. 2004
    ..To confirm the identity of the major metabolites of domperidone and to characterize the cytochrome P450s (CYPs) involved in their formation...
  25. doi request reprint Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer
    Wenjie Jessie Lu
    Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, Indiana University Simon Cancer Center, Indiana University School of Medicine, 1001 West 10th Street, Room 7123, Myers Building, Indianapolis, IN 46202, USA
    Breast Cancer Res Treat 131:473-81. 2012
    ..Relationships between tamoxifen metabolite concentrations and clinical outcomes may be complex, and the biologic mechanisms that underlie these relationships may include aromatase inhibition...
  26. pmc A penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotypes
    Lang Li
    Division of Biostatistics, Department of Medicine, School of Medicine, Indiana University, Indianapolis, IN
    Cancer Inform 9:93-103. 2010
    ..The power and recovery rate of the true partition for the mixture model approach are investigated in statistical simulation studies, where it outperforms another published method...
  27. doi request reprint Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells
    Chul Kim
    Department of Cellular and Integrative Physiology, Indiana Center for Vascular Biology and Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Antivir Ther 16:1335-9. 2011
    ..We examined the impact of these drugs on the expression levels of the proinflammatory, oxidative stress and apoptosis regulating genes in HCAECs...
  28. ncbi request reprint Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial
    Kyung Hoon Lee
    Division of Clinical Pharmacology, Indiana University School of Medicine, Wishard Memorial Hospital, 1001 West Tenth Street, Myers Building W7123, Indianapolis, IN 46202, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 791:245-53. 2003
    ..B 655 (1994) 261]. The coefficients of variation for the midpoint of the standard curve for each compound were less than 10%. This method was applied to a pharmacokinetic study of tamoxifen disposition in breast cancer patients...
  29. pmc In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole
    Landry K Kamdem
    Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
    Br J Clin Pharmacol 70:854-69. 2010
    ..Little information is available regarding the metabolic routes of anastrozole and the specific enzymes involved. We characterized anastrozole oxidative and conjugation metabolism in vitro and in vivo...
  30. pmc Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase)
    Wenjie Jessie Lu
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Drug Metab Dispos 38:1308-13. 2010
    ..Methadone is metabolized by CYP19 and may act as a potent inhibitor of CYP19 in vivo. These findings may contribute to variability in methadone clearance, to drug-drug interactions, and to side effects observed in individual patients...
  31. pmc Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial
    Samir K Gupta
    Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
    PLoS ONE 8:e60852. 2013
    ..Our preliminary in vitro and in vivo research suggests that pentoxifylline (PTX) reduces vascular inflammation and improves endothelial function in HIV-infected persons not requiring antiretroviral therapy...
  32. ncbi request reprint Clinical significance of the cytochrome P450 2C19 genetic polymorphism
    Zeruesenay Desta
    Division of Clinical Pharmacology, Indiana University School of Medicine, Wishard Hospital, Indianapolis 46202, USA
    Clin Pharmacokinet 41:913-58. 2002
    ..Finally, many studies have attempted to identify relationships between CYP2C19 genotype and phenotype and susceptibility to xenobiotic-induced disease, but none of these are compelling...
  33. doi request reprint Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis
    Marcelo F Montenegro
    Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil
    J Cardiovasc Pharmacol 58:647-53. 2011
    ..These results show that Tam and its metabolites cause acute vasorelaxation by inducing vasodilator prostanoids synthesis...
  34. pmc Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
    Rolf P Kreutz
    Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN, USA
    Clin Pharmacol 4:13-20. 2012
    ....
  35. ncbi request reprint Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen
    Young Chai Lim
    Division of Clinical Pharmacology, Indiana University School of Medicine, 1001 West 10th Street, WD Myers Bldg, W7123, Indianapolis, Indiana 46202, USA
    Cancer Chemother Pharmacol 55:471-8. 2005
    ..We, therefore, determined the effect of endoxifen and 4-OH-Tam on 17beta-estradiol (E2)-induced PR mRNA expression in an estrogen receptor-positive human breast cancer cell line...
  36. ncbi request reprint Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19
    Million Arefayene
    Department of Medicine Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Pharmacogenetics 13:199-206. 2003
    ..These data make possible future studies to elucidate the molecular mechanisms by which CYP2C19 can be induced in clinical settings and the consequences of genetic variability in its promoter...
  37. pmc Stereoselective and regiospecific hydroxylation of ketamine and norketamine
    Zeruesenay Desta
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA
    Xenobiotica 42:1076-87. 2012
    ..Large variations in HNK concentrations were observed suggesting that pharmacogenetics and/or metabolic drug interactions may play a role in therapeutic response...
  38. pmc In vitro cytochrome P450-mediated metabolism of exemestane
    Landry K Kamdem
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Drug Metab Dispos 39:98-105. 2011
    ..None of them markedly inhibited the formation of MI. In summary, exemestane seems to be metabolized to MI by multiple P450s that include CYP4A11 and CYP1A1/2, whereas its oxidation to MII is primarily mediated by CYP3A...
  39. ncbi request reprint Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity
    Million Arefayene
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Pharmacogenet Genomics 19:464-76. 2009
    ..We identified genetic variations in the IDO1 gene and evaluated their functional activities using in-vitro transfection studies...
  40. pmc Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz
    Doo Yeoun Cho
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Antimicrob Agents Chemother 55:1504-9. 2011
    ....
  41. pmc Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study
    Samir K Gupta
    Department of Medicine, Indiana Center for Vascular Biology and Medicine, Indiana University School of Medicine, Indianapolis, USA
    AIDS 24:1377-80. 2010
    ..Pentoxifylline may reverse HIV-related endothelial dysfunction by directly inhibiting the endothelial leukocyte adhesion pathway...
  42. doi request reprint Histoplasma capsulatum preferentially induces IDO in the lung
    Chadi A Hage
    Indiana University School of Medicine and Roudebush Veterans Administration Medical Center, Pulmonary Critical Care Medicine, Indianapolis, Indiana 46202, USA
    Med Mycol 51:270-9. 2013
    ..Histoplasma preferentially induces lung IDO, as early as one week after infection. IDO appears to modulate the immune response to Histoplasma infection...
  43. doi request reprint Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study
    Rolf P Kreutz
    Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana
    Pharmacotherapy 30:787-96. 2010
    ..To investigate the potential impact of proton pump inhibitors (PPIs) on the effectiveness of clopidogrel in preventing recurrent ischemic events after percutaneous coronary intervention (PCI) with stent placement...
  44. pmc Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index
    Fen Jiang
    Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, South Korea
    Br J Clin Pharmacol 75:244-53. 2013
    ....
  45. pmc Variability of heart rate correction methods for the QT interval
    Mehul Desai
    Division of Clinical Pharmacology, Department of Medicine, Indiana University, Indianapolis, IN, USA, and Department of Cardiological Sciences, St George s Hospital Medical School, London, UK
    Br J Clin Pharmacol 55:511-7. 2003
    ..To compare variability of heart rate-corrected QT intervals (QTc) using three different methods in a study of low-dose oral haloperidol...
  46. pmc Germline pharmacogenetics of tamoxifen response: have we learned enough?
    Zeruesenay Desta
    J Clin Oncol 25:5147-9. 2007
  47. ncbi request reprint The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN, 55905, USA
    Breast Cancer Res Treat 101:113-21. 2007
    ....
  48. ncbi request reprint Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis
    Kazuki Takada
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892, USA
    Arthritis Rheum 50:2202-10. 2004
    ..We conducted a retrospective cohort study to test whether genetic polymorphisms of these enzymes are associated with the toxicity of, and clinical response to, cyclophosphamide in patients with lupus nephritis...
  49. ncbi request reprint Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 23:9312-8. 2005
    ..Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown...
  50. pmc Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:5864-8. 2008
    ..We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer...

Research Grants5

  1. CYP2B6 genetic variations and drug interactions
    Zeruesenay Desta; Fiscal Year: 2007
    ..Together, these studies will lay the groundwork for improved therapy with a growing list of drugs that are metabolized by CYP2B6 through optimizing beneficial effects and avoiding adverse drug reactions. ..
  2. CYP2B6 genetic variations and drug interactions
    Zeruesenay Desta; Fiscal Year: 2009
    ..Together, these studies will lay the groundwork for improved therapy with a growing list of drugs that are metabolized by CYP2B6 through optimizing beneficial effects and avoiding adverse drug reactions. ..
  3. CYP2B6 genetic variations and drug interactions
    Zeruesenay Desta; Fiscal Year: 2010
    ..Together, these studies will lay the groundwork for improved therapy with a growing list of drugs that are metabolized by CYP2B6 through optimizing beneficial effects and avoiding adverse drug reactions. ..
  4. CYP2B6 genetic variations and drug interactions
    Zeruesenay Desta; Fiscal Year: 2010
    ..Together, these studies will lay the groundwork for improved therapy with a growing list of drugs that are metabolized by CYP2B6 through optimizing beneficial effects and avoiding adverse drug reactions. ..